NZ598702A - A micro-rna family that modulates fibrosis and uses thereof - Google Patents

A micro-rna family that modulates fibrosis and uses thereof

Info

Publication number
NZ598702A
NZ598702A NZ598702A NZ59870208A NZ598702A NZ 598702 A NZ598702 A NZ 598702A NZ 598702 A NZ598702 A NZ 598702A NZ 59870208 A NZ59870208 A NZ 59870208A NZ 598702 A NZ598702 A NZ 598702A
Authority
NZ
New Zealand
Prior art keywords
mir
sequence
antisense oligonucleotide
micro
medicament
Prior art date
Application number
NZ598702A
Inventor
Eric Olson
Rooij Eva Van
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to NZ61479108A priority Critical patent/NZ614791A/en
Priority claimed from NZ583024A external-priority patent/NZ583024A/en
Publication of NZ598702A publication Critical patent/NZ598702A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

598702 Disclosed is the use of an antisense oligonucleotide for preparation of a medicament for treating pathologies or deficiencies that are characterized by a loss, lack, or underproduction of collagen, wherein the antisense oligonucleotide comprises a sequence that is at least partially complementary to a miR-29a (uagcaccaucugaaaucggu), miR-29b (uagcaccauuugaaaucagu), or miR-29c (uagcaccauuugaaaucggu) sequence. Further disclosed is the use of an antisense oligonucleotide for preparation of a medicament for increasing collagen deposition in a tissue for treatment of natural aging and stretch marks. Further disclosed is a composition formulated for topical administration comprising a pharmaceutically acceptable carrier and an antisense oligonucleotide comprising a sequence that is at least partially complementary to a miR-29a, miR-29b, and/or miR-29c sequence.
NZ598702A 2007-07-31 2008-07-31 A micro-rna family that modulates fibrosis and uses thereof NZ598702A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ61479108A NZ614791A (en) 2007-07-31 2008-07-31 A micro-rna family that modulates fibrosis and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95291707P 2007-07-31 2007-07-31
US98030307P 2007-10-16 2007-10-16
US4701408P 2008-04-22 2008-04-22
NZ583024A NZ583024A (en) 2007-07-31 2008-07-31 An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof

Publications (1)

Publication Number Publication Date
NZ598702A true NZ598702A (en) 2014-01-31

Family

ID=50619560

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598702A NZ598702A (en) 2007-07-31 2008-07-31 A micro-rna family that modulates fibrosis and uses thereof
NZ61479108A NZ614791A (en) 2007-07-31 2008-07-31 A micro-rna family that modulates fibrosis and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ61479108A NZ614791A (en) 2007-07-31 2008-07-31 A micro-rna family that modulates fibrosis and uses thereof

Country Status (3)

Country Link
CN (1) CN105030808B (en)
NZ (2) NZ598702A (en)
PL (1) PL2182969T3 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105420405B (en) * 2015-12-30 2018-12-07 山东农业大学 The cow's serum microRNA molecule of milk cow Fatty Liver Disease and cow in perinatal period related metabolic diseases label
WO2017219168A1 (en) * 2016-06-19 2017-12-28 毛侃琅 Lentiviral vector for knocking down mirna-29a and mir-152 expressions, and application thereof
WO2019109026A1 (en) * 2017-11-30 2019-06-06 MiRagen Therapeutics, Inc. miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSIS
CN108690846A (en) * 2018-04-17 2018-10-23 上海大学 Inhibit the application of MiR-29b gene expressions
CN109762883B (en) * 2019-01-31 2020-01-21 温州医科大学 Application of plasma/serum exosome hsa-miRNA-29-3p as glaucoma diagnosis marker
CN110283901A (en) * 2019-07-25 2019-09-27 青岛大学 MiRNA probe compositions, Primer composition and diagnosis of coronary heart disease kit for diagnosis of coronary heart disease
CN111249466B (en) * 2020-03-14 2022-04-15 浙江大学医学院附属第一医院 Application of tanshinone IIA and miR-29b inhibitor in preparation of medicine for treating tendon adhesion
CN111647656A (en) * 2020-05-15 2020-09-11 华中科技大学同济医学院附属同济医院 Application of mir-29a gene in detection of liver cancer and liver fibrosis and construction method of conditional knock-in mouse of gene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281261B2 (en) * 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain

Also Published As

Publication number Publication date
CN105030808B (en) 2018-12-14
NZ614791A (en) 2015-03-27
CN105030808A (en) 2015-11-11
PL2182969T3 (en) 2017-06-30

Similar Documents

Publication Publication Date Title
NZ598702A (en) A micro-rna family that modulates fibrosis and uses thereof
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
EP3210633A3 (en) Compositions and their uses directed to huntingtin
MX2010014234A (en) Pyrazole compounds 436.
NZ624783A (en) Modulation of huntingtin expression
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
TW200635924A (en) Chemical compounds
UA105644C2 (en) Methods of treating pulmonary disorders with liposomal amikacin formulations
MX2011012122A (en) Thiophene derivatives.
MY169564A (en) Substituted dihydropyrazolones and their use
MY143795A (en) Tetrahydropyridoindole derivatives
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
WO2007131232A3 (en) Compositions and their uses directed to ptpr alpha
WO2008045559A3 (en) Methods of treating oral mucositis
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
TNSN08506A1 (en) Substituted carboxamides
MX2009006325A (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents.
TW200942529A (en) Pyrrolidinyl derivatives and uses thereof
PT1638582E (en) Use of hyaluronic acid for preparing compositions for treating recurrent oral cavity aphthas
WO2007036771A3 (en) Pantoprazole free acid form iii
MX2008015323A (en) Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association.
WO2011028799A3 (en) Ganglioside transmucosal formulations
WO2007144889A3 (en) Treatment of neurofibromatosis
DE502007003367D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INCONTINENCE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 JUL 2015 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20140507

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 1018264, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 201 WEST 7TH STREET, AUSTIN, TX 78701, US

Effective date: 20140808

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2016 BY CPA GLOBAL

Effective date: 20150620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2017 BY CPA GLOBAL

Effective date: 20160617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2018 BY CPA GLOBAL

Effective date: 20170615

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2019 BY CPA GLOBAL

Effective date: 20180614

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2020 BY CPA GLOBAL

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JUL 2021 BY CPA GLOBAL

Effective date: 20200723

LAPS Patent lapsed